Subsequently, the oral CHK1 inhibitor BBI-2779 was further applied in a mouse gastric cancer model containing FGFR2 ecDNA, confirming that BBI-2779 can inhibit gastric cancer growth and cause sustained tumor regression in mice (63). Here, FGFR2 is linked to gastric cancer.